CrystalsFirst
Marburg
About CrystalsFirst
CrystalsFirst is redefining small molecule drug discovery with its MAGNET Platform, a breakthrough technology platform. By integrating proprietary structural biology, and generative AI, we identify novel druggable binding pockets and precisely design molecules for even the most challenging targets. At the core of our platform is a “crystal structure first” strategy, enabling structure-based drug discovery from the outset. By leveraging high-resolution structural insights, large-scale computational modeling, and AI-driven molecular design, we accelerate the identification and optimization of lead compounds with superior therapeutic potential. By combining these synergistic technologies, the MAGNET Platform enhances efficiency, reduces risk, and significantly increases the probability of identifying first-in-class and best-in-class therapeutics.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $918.5K
- Funding stage: Seed
- Last round: Non-Equity Assistance (Aug 2022)
- Website: crystalsfirst.com
- Phone: +49 6421 968814 0
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/crystalsfirst-3617 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.